Document is current

Article History

Received: 28 December 2022

Accepted: 1 March 2024

First Online: 7 April 2024

Competing interests

: M.Y. has received grant/research support (to Johns Hopkins) from Bristol-Myers Squibb, Incyte and Genentech; has received honoraria from Genentech, Exelixis, Eisai, AstraZeneca, Replimune and Hepion; and has equity in Adventris. T.U.M. currently serves, or at any point in the past has served, on advisory and/or data safety monitoring boards for Rockefeller University, Regeneron, AbbVie, Merck, Bristol-Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, DrenBio, Glenmark, Simcere, Surface, G1 Therapeutics, NGM Bio, DBV Technologies, Arcus, Fate, Ono, Larkspur, Avammune and Astellas and has research grants from the National Institutes of Health (National Cancer Institute), the Cancer Research Institute, Regeneron, Genentech, Bristol-Myers Squibb, Merck and Boehringer Ingelheim. E.J.G. has served as a member of scientific advisory boards for AbbVie, Abbott Diagnostics, Aligos, Arbutus, Arrowhead, Assembly, Avalia, ClearB Therapeutics, Dicerna, Enanta, Gilead Sciences, GlaxoSmithKline, Intellia, Janssen, Merck, Novartis, Genentech-Roche, Vaccitech, Ventorx, Vir Biotechnology and Virion Therapeutics. He is a speaker for AbbVie, Abbott Diagnostics, Gilead Sciences and Intellia. R.P.-L., J.Y., N.C., S.R., J.P., A.P.-P. and N.Y.S. are either current or previous Geneos employees. A.P.-P. and N.Y.S. are listed as inventors on several pending applications related to the vaccine platform presented in this study. D.H.S. and L.T.K. have no disclosures to report. E.J.F. is on the scientific advisory board of Viosera Therapeutics/Resistance Bio and is a consultant for Mestag Therapeutics and Merck. E.M.J. has received personal fees from Achilles, Dragonfly, the Parker Institute for Cancer Immunotherapy, the Cancer Prevention and Research Institute of Texas, Surge, HDT Bio, Neuvogen, NeoTx, Mestag and Medical Home Group. She has research grants from Lustgarten, Genentech, Bristol-Meyers Squibb and Break Through Cancer outside the submitted work. She receives other support from Abmeta and Adventris. G.B., J.L. and J.N. are full-time employees of Personalis, Inc. I.C. has a consultant role with Geneos; she has served as an advisor and/or a member of the data safety review board for Coherus, Exscientia AI, Riboscience and the University of Utah Therapeutic Accelerator Hub. J.T.C. is a paid statistical consultant for Geneos Therapeutics. D.B.W. has received grant funding, participates in industry collaborations, has received speaking honoraria and has received fees for consulting, including serving on scientific review committees. Remunerations received by D.B.W. include direct payments and equity/options. D.B.W. also discloses the following associations with commercial partners: Geneos (consultant/advisory board), AstraZeneca (advisory board, speaker), Inovio (board of directors, consultant), BBI/Sumitomo Dainippon (advisory board), Flagship (consultant), Pfizer (advisory board) and Advaccine (consultant).